Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B

Yuki, Satoshi; Shinozaki, Kazuo; Kashiwada, Tomomi; Kusumoto, Tetsuya; Iwatsuki, Masaaki; Satake, Hironaga; Kobayashi, Kazuma; Esaki, Taito; Nakashima, Yasuhiro; Kawanaka, Hirofumi; Emi, Yasunori; Shimokawa, Mototsugu; Makiyama, Akitaka; Saeki, Hiroshi; Oki, Eiji; Baba, Hideo; Mori, Masaki

doi:10.1007/s00280-019-03991-3

Cited by 14 publications

(35 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last decade, early detection of gastric cancer by health screening systems and standardization of adjuvant treatment have reduced risk of peritoneal recurrence and improved prognosis 8,10‐12 . However, percentages of hematogenous and nodal recurrences increased with changes in characteristics of Asian gastric cancer, particularly by eradication of Helicobacter pylori , and reduction of peritoneal recurrences by S‐1 adjuvant 13,14 …”

Section: Discussionmentioning

confidence: 99%

Survival times are similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resections for gastric cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Survival times are similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resections for gastric cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The patients treated in the phase III studies received trastuzumab plus cisplatin or oxaliplatin plus capecitabine or 5-FU. 6,14,28,32 Seven phase II studies, 23,26,27,[33][34][35][36] five retrospective studies, 19,20,22,25,37 and a prospective observational study 21 were also included. Four phase II studies used S-1, with two in combination with cisplatin 23,35 and two with oxaliplatin.…”

Section: Features Of the Studies Analyzedmentioning

confidence: 99%

“…Safety comparison across the trials analyzed. See also 6,15,17,[19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37] AEs, adverse events; SAEs, serious adverse events; TEAEs, treatment-emergent adverse events; Tx, treatment. Considerations by tumor location among studies of trastuzumab plus fluoropyrimidine plus platin Among 12 studies 6,14,[28][29][30][31][32][33][34][35][36][37] in which gastric cancer was the most common, grade !3 AEs ranged from 44% to 84% (Tables 1 and 2).…”

Section: Considerations By Geographical Regionmentioning

confidence: 99%

“…Objective response rate (ORR) 6,14,[19][20][21]23,[25][26][27][28][29][30][31][32][33][34][35][36][37] ranged from 39% to 82%, median progression-free survival (PFS) 6,[19][20][21]23,[25][26][27][28][29][30][31][32][33][34][35][36][37] from 5.7 to 11.6 months, and median overall survival (OS) 6,[19][20][21]23,[25][26][27][28][29][30][31][32][33]…”

Section: Trastuzumab Plus Fluoropyrimidine Plus Platinummentioning

confidence: 99%

See 1 more Smart Citation

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma

et al. 2022

View full text Add to dashboard Cite

Since completion of the Trastuzumab for Gastric Cancer study, trastuzumab with doublet chemotherapy (a fluoropyrimidine and a platinum) has been the gold-standard first-line therapy for patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-positive (HER2þ) gastroesophageal adenocarcinoma (GEA). The safety and efficacy of 23 studies of first-line trastuzumab plus doublet chemotherapy, without checkpoint inhibitors (n ¼ 19) or with checkpoint inhibitors (n ¼ 4), conducted in patients with locally advanced unresectable or metastatic HER2þ GEA, including phase II/III, prospective, and retrospective observational studies, were summarized. In studies without checkpoint inhibitors, the median duration of trastuzumab treatment ranged from 19.5 to 39.0 weeks and from 15.3 to 30.0 weeks for chemotherapy. In studies with checkpoint inhibitors, the median duration of pembrolizumab/trastuzumab/chemotherapy was 30 weeks, and 18 weeks for chemotherapy. In studies without checkpoint inhibitors, treatment-emergent adverse events (TEAEs) of grade !3 ranged from 32% to 84%. Serious adverse events (SAEs) ranged from 15% to 39%. Adverse events resulting in discontinuation ranged from 0% to 30%. Treatment-related deaths occurred in 0%-9% of patients. In studies with checkpoint inhibitors, TEAEs of grade !3 were 57%. SAEs ranged from 31% to 38%. Adverse events resulting in discontinuation ranged from 5% to 24%. Treatment-related deaths occurred in 0%-3% of patients. In studies without checkpoint inhibitors, objective response rate (ORR) ranged from 39% to 82%, median progression-free survival (PFS) from 5.7 to 11.6 months, and median overall survival (OS) from 11.2 to 27.6 months. In studies with checkpoint inhibitors, ORR ranged from 39% to 86%, median PFS from 8.0 to 13.0 months, and median OS from 19.3 to 27.3 months. This review provides a historical benchmark on safety and efficacy of available first-line chemotherapy-based standard of care for patients with locally advanced unresectable or metastatic HER2þ GEA.

show abstract

“…Several phase 2 trials have tested different chemotherapies in combination with trastuzumab as first line therapy in advanced or metastatic gastric or GEJ cancer. Studies that combined trastuzumab and different chemotherapies and treatment outcomes are summarized in Table 1 [ 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ].…”

Section: Treatment-related Biomarkers—molecular Targeted Therapymentioning

confidence: 99%

Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives

Niclauss

Gütgemann

Dohmen

et al. 2021

Cancers

View full text Add to dashboard Cite

Overall survival of gastric cancer remains low, as patients are often diagnosed with advanced stage disease. In this review, we give an overview of current research on biomarkers in gastric cancer and their implementation in treatment strategies. The HER2-targeting trastuzumab is the first molecular targeted agent approved for gastric cancer treatment. Other promising biomarkers for targeted therapies that have shown relevance in clinical trials are VEGF and Claudin 18.2. Expression of MET has been shown to be a negative prognostic factor in gastric cancer. Targeting the PD-1/PD-L1 pathway with immune checkpoint inhibitors has proven efficacy in advanced gastric cancer. Recent technology advances allow the detection of circulating tumor cells that may be used as diagnostic and prognostic indicators and for therapy monitoring in gastric cancer patients. Prognostic molecular subtypes of gastric cancer have been identified using genomic data. In addition, transcriptome profiling has allowed a comprehensive characterization of the immune and stromal microenvironment in gastric cancer and development of novel risk scores. These prognostic and predictive markers highlight the rapidly evolving field of research in gastric cancer, promising improved treatment stratification and identification of molecular targets for individualized treatment in gastric cancer.

show abstract

Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B

Cited by 14 publications

References 20 publications

Survival times are similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resections for gastric cancer

Survival times are similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resections for gastric cancer

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma

Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives

Contact Info

Product

Resources

About